Show simple item record

dc.contributor.authorSugeeta, Sukumar S.
dc.contributor.authorSharma, Anand
dc.contributor.authorNg, Kenrick
dc.contributor.authorNayak, Arvind
dc.contributor.authorVasdev, Nikhil
dc.date.accessioned2021-10-13T09:30:04Z
dc.date.available2021-10-13T09:30:04Z
dc.date.issued2021-09-28
dc.identifier.citationSugeeta , S S , Sharma , A , Ng , K , Nayak , A & Vasdev , N 2021 , ' Biomarkers in Bladder Cancer Surveillance ' , Frontiers in Surgery , vol. 8 , 735868 . https://doi.org/10.3389/fsurg.2021.735868
dc.identifier.issn2296-875X
dc.identifier.otherPURE: 26090646
dc.identifier.otherPURE UUID: b241651f-bd25-47af-b80e-ee86dd4bcfe5
dc.identifier.otherJisc: 137622773e19401eb7964d07d2fbd494
dc.identifier.urihttp://hdl.handle.net/2299/25122
dc.description© 2021 Sugeeta, Sharma, Ng, Nayak and Vasdev. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). https://creativecommons.org/licenses/by/4.0/
dc.description.abstractAim: This is a narrative review with an aim to summarise and describe urinary biomarkers in the surveillance of non-muscle-invasive bladder cancer (NMIBC). It provides a summary of FDA-approved protein biomarkers along with emerging ones which utilise genetic, epigenetic and exosomal markers. We discuss the current limitations of the available assays. Background: Current guidelines advice a combination of cystoscopy, imaging, and urine cytology in diagnosis and surveillance. Although cytology has a high specificity, it is limited by low sensitivity particularly in low grade tumours. There are six FDA-approved urinary assays for diagnosis and surveillance of bladder cancer. They have shown to improve sensitivity and specificity to be used alongside cytology and cystoscopy but have a lower specificity in comparison to cytology and false positives often occur in benign conditions. Recent developments in laboratory techniques has allowed for use of markers which are RNA-, DNA-based as well as extracellular vesicles in the past decade. Methods: Using the PubMed/Medline search engines as well as Google Scholar, we performed an online search using the terms “bladder cancer,” “non-muscle invasive bladder cancer,” and “urine biomarkers” with filter for articles in English published up to May 2021. Systematic reviews and original data of clinical trials or observational studies which contributed to the development of the biomarkers were collated. Results: Biomarkers identified were divided into FDA-approved molecular biomarkers, protein biomarkers and gene-related biomarker with a table summarising the findings of each marker with the most relevant studies. The studies conducted were mainly retrospective. Due to the early stages of development, only a few prospective studies have been done for more recently developed biomarkers and limited meta-analyses are available. Therefore a detailed evaluation of these markers are still required to decide on their clinical use. Conclusion: Advancements of analytical methods in BC has driven the research towards non-invasive liquid-based biomarkers in adjunct to urine cytology. Further large prospective studies are required to determine its feasibility in a clinical setting as they are not effective when used in isolation as they have their limitation. With the ongoing pandemic, other than reduction in costs and increased accuracy, the need for biomarkers to cope with delay in cystoscopies in diagnosis and surveillance is crucial. Thus clinical trials with direct comparison is required to improve patient care.en
dc.format.extent11
dc.language.isoeng
dc.relation.ispartofFrontiers in Surgery
dc.subjectSurgery
dc.subjectbiomarker
dc.subjectbladder cancer
dc.subjectsurveillance
dc.subjectnon-muscular invasive bladder cancer
dc.subjectcancer screening
dc.titleBiomarkers in Bladder Cancer Surveillanceen
dc.contributor.institutionDepartment of Clinical, Pharmaceutical and Biological Science
dc.contributor.institutionExtracellular Vesicle Research Unit
dc.contributor.institutionBasic and Clinical Science Unit
dc.contributor.institutionCentre for Health Services and Clinical Research
dc.contributor.institutionSchool of Life and Medical Sciences
dc.description.statusPeer reviewed
rioxxterms.versionVoR
rioxxterms.versionofrecordhttps://doi.org/10.3389/fsurg.2021.735868
rioxxterms.typeOther
herts.preservation.rarelyaccessedtrue


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record